TL;DR: Aetna, a CVS Health company, modified CPB 0910 covering extended-release buprenorphine injectables for opioid use disorder, effective January 5, 2026. Billing teams who submit HCPCS codes J0577, J0578, Q9991, and Q9992 need to verify their patients meet the updated step-therapy and prior authorization requirements before claims go out.
Aetna's CPB 0910 buprenorphine implant and extended-release buprenorphine injectable coverage policy now formally addresses two distinct products: Sublocade (billed under Q9991 and Q9992) and Brixadi (billed under J0577 and J0578). The real issue here is that each product carries different step-therapy prerequisites — and mixing them up on a claim is a fast path to denial. The effective date is January 5, 2026, and if your billing team hasn't updated charge capture to reflect the product-specific criteria, you're already behind.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Buprenorphine Implant and Extended-Release Buprenorphine Injectables |
| Policy Code | CPB 0910 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | High |
| Specialties Affected | Addiction medicine, primary care, behavioral health, office-based opioid treatment (OBOT) practices |
| Key Action | Verify step-therapy documentation for each product before billing J0577, J0578, Q9991, or Q9992 on any Aetna claim after January 5, 2026 |
Aetna Extended-Release Buprenorphine Coverage Criteria and Medical Necessity Requirements 2026
The updated Aetna buprenorphine injectable coverage policy draws a clear line between Sublocade and Brixadi. They are not interchangeable under this policy — and Aetna's medical necessity criteria treat them differently.
For Sublocade (Q9991 / Q9992): Aetna covers the once-monthly injectable for moderate-to-severe opioid use disorder. The member must have already started treatment with a transmucosal buprenorphine-containing product. They must also be on a stable dose of buprenorphine for at least seven days before Sublocade is administered. On top of that, Sublocade must be used as part of a complete treatment program — including drug testing, counseling, and psychosocial support.
That last requirement is not a checkbox. Aetna will look for documentation showing the member is enrolled in wraparound services. If your practice bills Q9991 or Q9992 without evidence of counseling or psychosocial support in the record, expect a claim denial.
For Brixadi (J0577 / J0578): Aetna covers the extended-release subcutaneous injection for moderate-to-severe opioid use disorder in two scenarios. Either the member has received a single dose of a transmucosal buprenorphine product, or the member is already being treated with buprenorphine. Note that Brixadi's on-ramp is shorter than Sublocade's — it does not require seven days of stable dosing. That distinction matters clinically and for prior authorization documentation.
J0577 covers Brixadi doses for periods of seven days or less. J0578 covers Brixadi for periods greater than seven days and up to 28 days. Make sure your team is using the right code for the dispensed duration. Billing J0578 for a weekly dose is a simple, avoidable error that triggers a denial.
Prior authorization is standard practice for specialty injectables under commercial Aetna plans. If your practice treats Aetna members with either Sublocade or Brixadi, build prior auth workflows that document the specific step-therapy requirements for each product. Do not assume the same auth template works for both.
Aetna Buprenorphine Implant and Injectable Exclusions and Non-Covered Indications
Aetna is explicit here. The buprenorphine implant — along with the once-monthly injectable outside the criteria described above — is considered experimental and investigational for all other indications.
That means any use of the implant (CPT 11981, 11983, or HCPCS G0516, G0517, G0518) falls outside covered services under CPB 0910 unless Aetna revises that position. The same applies to the once-monthly injectable used for anything other than moderate-to-severe OUD under the conditions listed.
If your practice performs buprenorphine implant insertions or removals, those procedures are not covered under this policy. Billing 11981 or G0516 for an Aetna member expecting reimbursement will result in denial. Review your patient financial counseling process to make sure Aetna members understand this before the procedure happens.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Sublocade for moderate-to-severe OUD — with ≥7 days stable transmucosal buprenorphine | Covered | Q9991, Q9992 | Must include drug testing, counseling, and psychosocial support |
| Brixadi for moderate-to-severe OUD — initiated with single transmucosal buprenorphine dose | Covered | J0577, J0578 | No 7-day stability requirement |
| Brixadi for moderate-to-severe OUD — already on buprenorphine treatment | Covered | J0577, J0578 | Use J0577 for ≤7 days; J0578 for >7 and ≤28 days |
| Buprenorphine implant (all indications) | Experimental / Not Covered | 11981, 11983, G0516, G0517, G0518 | Considered experimental and investigational under CPB 0910 |
| Once-monthly injectable for indications other than qualifying OUD criteria | Experimental / Not Covered | Q9991, Q9992 | Off-label use not covered |
Aetna Extended-Release Buprenorphine Billing Guidelines and Action Items 2026
These are the steps your billing team needs to take now. The effective date has already passed.
| # | Action Item |
|---|---|
| 1 | Audit your Aetna buprenorphine claims from January 5, 2026 forward. Check every claim with J0577, J0578, Q9991, or Q9992 to confirm the documentation supports the product-specific step-therapy criteria. If you submitted claims before verifying stability requirements for Sublocade, pull those accounts now. |
| 2 | Update charge capture to separate Sublocade and Brixadi workflows. These two products have different coverage criteria. Your team should not be routing them through the same auth or documentation checklist. Build distinct templates — one for Q9991/Q9992 and one for J0577/J0578. |
| 3 | Confirm prior authorization documentation matches the right product criteria. For Sublocade, your auth request must show the member was on a stable transmucosal buprenorphine dose for at least seven days. For Brixadi, you need evidence of a transmucosal buprenorphine initiation dose or existing buprenorphine treatment. Submitting Sublocade criteria for a Brixadi auth — or vice versa — will slow down or kill the auth. |
| 4 | Add drug testing, counseling, and psychosocial support documentation to every Sublocade claim. This is a hard medical necessity requirement under the policy. The clinical record must show these services are happening. Use G2086, G2087, or G2088 (office-based OUD treatment codes) where appropriate to demonstrate the wraparound program exists. |
| 5 | Stop billing implant-related codes for Aetna members. CPT 11981, 11983, and HCPCS G0516, G0517, G0518 are not covered under CPB 0910. Remove these from any Aetna-specific charge capture sets for OUD treatment. If your practice offers implants, update your financial counseling script so Aetna members know this is a non-covered service before you proceed. |
| 6 | Verify HCPCS code selection for Brixadi duration. J0577 is for doses covering seven days or less. J0578 is for doses covering more than seven days and up to 28 days. The dose duration determines the code — not the drug itself. Train your billing staff on this distinction before they touch the next batch of Aetna claims. |
| 7 | Review your denial management queue for OUD claims. If Aetna denied any buprenorphine injectable claims in the past few months, check whether the denial was based on the criteria that CPB 0910 now formalizes. Some of those may be appealable with the right supporting documentation. |
If you're not sure how this policy applies across your patient mix — especially if you treat both Sublocade and Brixadi patients — talk to your compliance officer before submitting another batch of Aetna claims.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Extended-Release Buprenorphine Under CPB 0910
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J0577 | HCPCS | Injection, buprenorphine extended-release (Brixadi), less than or equal to 7 days of therapy |
| J0578 | HCPCS | Injection, buprenorphine extended-release (Brixadi), greater than 7 days and up to 28 days of therapy |
| Q9991 | HCPCS | Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg |
| Q9992 | HCPCS | Injection, buprenorphine extended-release (Sublocade), greater than 100 mg |
Other CPT Codes Related to CPB 0910
These codes are referenced in the policy but are not covered under the current criteria for Aetna members. Implant insertion and removal procedures are considered experimental and investigational.
| Code | Type | Description |
|---|---|---|
| 11981 | CPT | Insertion, non-biodegradable drug delivery implant |
| 11983 | CPT | Removal with reinsertion, non-biodegradable drug delivery implant |
| +20700 | CPT | Manual preparation and insertion of drug-delivery device(s), deep (e.g., subfascial) — add-on code |
| 96372 | CPT | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
Other HCPCS Codes Related to CPB 0910
| Code | Type | Description |
|---|---|---|
| G0516 | HCPCS | Insertion of non-biodegradable drug delivery implants, 4 or more (subdermal rod implants) |
| G0517 | HCPCS | Removal of non-biodegradable drug delivery implants, 4 or more (subdermal implants) |
| G0518 | HCPCS | Removal with reinsertion, non-biodegradable drug delivery implants, 4 or more (subdermal implants) |
| G2086 | HCPCS | Office-based treatment for opioid use disorder, including development of treatment plan and care coordination |
| G2087 | HCPCS | Office-based treatment for opioid use disorder, including care coordination and individual therapy |
| G2088 | HCPCS | Office-based treatment for opioid use disorder, including care coordination and individual therapy (additional code) |
| J0571 | HCPCS | Buprenorphine, oral, 1 mg |
| J0572 | HCPCS | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine |
| J0573 | HCPCS | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine |
| J0574 | HCPCS | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine |
| J0575 | HCPCS | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine |
| J0592 | HCPCS | Injection, buprenorphine hydrochloride, 0.1 mg |
Key ICD-10-CM Diagnosis Codes
Aetna's CPB 0910 applies across the full F11 opioid-related disorders category. The policy includes 90 ICD-10-CM codes spanning F11.10 through F11.99. The table below lists the primary code ranges — confirm your specific fifth-character codes match the patient's documented clinical presentation.
| Code Range | Description |
|---|---|
| F11.10–F11.19 | Opioid abuse, uncomplicated through unspecified opioid-induced disorder |
| F11.20–F11.29 | Opioid dependence, uncomplicated through unspecified opioid-induced disorder |
| F11.30–F11.39 | Opioid use, unspecified, uncomplicated through unspecified opioid-induced disorder |
| F11.40–F11.49 | Opioid-induced disorder, uncomplicated through unspecified |
| F11.50–F11.59 | Opioid-induced psychotic disorder, unspecified through other |
| F11.60–F11.69 | Opioid-induced disorder (additional subcategories) |
Use the most specific F11 code that matches your documentation. Opioid use disorder billing under Aetna requires the right specificity at the fifth character — F11.20 (unspecified, uncomplicated) will not support the same claims as F11.21 or F11.22 if the record shows a more specific presentation.
Get the Full Picture for CPT 11981
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.